

Cardiac arrhythmogenesis: a tale of two clocks?

Ming Lei¹ and Christopher L.-H. Huang²

¹Department of Pharmacology, University of Oxford, Oxford OX1 3QT, ²Physiological Laboratory and Department of Biochemistry, University of Cambridge, Cambridge CB2 3EG; United Kingdom.

Around 3.7 million individuals worldwide die each year from cardiac arrhythmias; this exceeds the total numbers of deaths from all cancers in the Western world¹. Despite major progress in interventional including device therapy, anti-arrhythmic medication remains **central** to their management. In the late 1960s Miles Vaughan Williams classified the existing drugs then used to treat cardiac arrhythmias^{2,3}. This was widely adopted worldwide in both clinical management and as guidance for the development of new drugs that have saved countless lives.

However, the subsequent 50 years witnessed a heightened understanding of arrhythmic mechanisms and their biomolecular basis^{4,5}. This was accompanied by discovery of the considerable number of their underlying membrane ion channel and intracellular ion transport regulatory protein molecules and characterisation of their precise roles in normal and arrhythmic activity⁶. Emerging evidence over the last two decades strongly suggests that this normal electrical function of the heart is the result of dynamic **and orchestrated** interactions **between** membrane ion channels and intracellular ion transport regulatory protein molecules **within** a complex molecular network⁷. These insights **both** enhanced our understanding of the pharmacological mechanism of actions of existing drugs **and** offered **novel** physiological targets for **drug development**. Yet, clinical practice may not have optimally benefitted from these advances. Arrhythmias remain a major clinical problem. Their therapy has often lagged progress in many other areas of cardiological medicine.

Might such **a** lack of progress reflect a **lack** of clarity **or of** organisation of these more recent and myriad findings into a coherent hypothesis that might relate fundamental physiological mechanisms to clinical **therapy**? Thus the Vaughan-Williams scheme had embedded such a simplified yet pragmatic working model for cardiomyocyte function in terms of then established drugs. It regarded arrhythmia as a consequence of a disruption of normal **cardiac** electrophysiological activation. **This** primarily invoked normal and abnormal function in surface membrane ion channels. It then organised these fundamental physiological mechanisms into a simple system effectively constituting what might be termed a surface membrane (M) clock (cf⁸). Individual drugs were identified with then known ion channels and their possible actions on these activation and recovery processes. Such cyclically operating system are exemplified elsewhere by the circadian rhythms ubiquitous in biological systems, **in which** misalignments **produce** negative functional effects.

Although possibly oversimplified **the Vaughan-Williams scheme** had provided a coherent framework for diagnostic analysis and therapeutic action, often thereby directly facilitating clinical management⁹. Any over-simplification of the actual physiological or clinical situation was mitigated by the advantages offered by **its** clarity and simplicity, as well as its explicit and legitimate correlations of particular therapies with then known arrhythmic targets (referenced in⁷). It has **thus remained** the most useful, clinically and pedagogically popular amongst classifications of anti-arrhythmic drugs (AAD). Furthermore, the few subsequent attempts to clarify these links between mechanisms of actions and therapeutic effects, exemplified by the important publication from a Working Group of the European Society of Cardiology in 1991 achieved limited success¹⁰.

We speculate that our recent modernized Oxford classification⁷ and its future developments may offer **its** pragmatic successor. **It seeks** to capture the greater proportion of **both currently employed and** the more recently discovered therapeutic and investigational agents. **Its classification** maps directly onto the recent, important and extensive, insights and developments in cardiac electrophysiology and pharmacology. The latter have now often succeeded in identifying particular arrhythmic phenotypes

with abnormalities in particular ion channels, ion transporters and signalling agents that might offer real or potential therapeutic targets at the molecular level. **Embedded within it is** an updated model for normal and abnormal cardiac electrophysiological activity **that relates directly** to its suggested classes of drug targets and their established and potential therapeutic effects (Figure 1). **Thus, it added** to the original M-clock, a further oscillator reflecting intracellular events **contributing to cardiac activity**. Many of these bear on Ca^{2+} homeostasis¹¹ **and thus** thereby **come together into** an additional, ‘ Ca^{2+} (C)-clock’. Normal cardiac excitation **then** requires the cyclic events in the two clocks **to be aligned**. Disruption in this alignment leads to arrhythmia.

Table 1 derives a simplification of the modernized Oxford classification⁷ directed at drugs in current clinical use as opposed to investigational agents. It reflects its organisation in retaining but extending the original Vaughan Williams classes **I-IV bearing respectively** on action potential activation, autonomic action, action potential recovery and Ca^{2+} current respectively. It then adds class 0, V, VI, VII agents modifying sino-atrial automaticity, mechanosensitive and connexin associated channels, as well as upstream modulatory targets. Thus, it first incorporates the original sequential cycles of surface membrane voltage-gated Na^+ channel-mediated action potential (AP) depolarisation, and refractoriness, and K^+ channel-mediated repolarisation paced by SAN activity. However, this membrane (M-) clock is also linked to tissue level intercellular as opposed to intracellular processes that also affect action potential conduction. Pro-arrhythmic AP conduction slowing thus can follow both reduced inward Na^+ current compromising AP activation or anatomical changes altering connexin (Cx)-dependent intercellular conductances, thereby causing functionally or anatomically defined re-entrant pathways⁹. Second, it also incorporates the depolarisation-induced activation of L-type Ca^{2+} channels that produces the action potential plateau. The latter activation events are also strategic in that they *feed-forward* to the C-clock whose operation is thus normally synchronously initiated and terminated by events associated with corresponding activation and recovery events in the M-clock. Thus the resulting Ca^{2+} influx triggers ryanodine (RyR2) or inositol trisphosphate receptor-mediated SR Ca^{2+} release elevating cytosolic $[\text{Ca}^{2+}]$. This is terminated and reversed with repolarisation. Ca^{2+} -ATPase mediated Ca^{2+} re-uptake into the SR or Na^+ - Ca^{2+} exchanger mediated expulsion into the extracellular space then restores resting cytosolic $[\text{Ca}^{2+}]$ completing its duty cycle¹¹.

Arrhythmias **directly result from** abnormal automaticity originating from specialized conducting SAN, atrioventricular node (AVN) or Purkinje fibres, or pathological generation or conduction of excitation by atrial and ventricular cardiomyocytes, involving the M-clock. However, particular intracellular events forming the resulting intracellular C-clock *feed-back* onto specific M-clock components, with potential pro-arrhythmic consequences. Altered Ca^{2+} channel function itself may underly pro-arrhythmic, triggering, early after-depolarization (EAD) phenomena during late phase 2 or early phase 3 often of prolonged APs in common with increased late Na^+ or decreased K^+ current contributions to prolonged electrocardiographic QT intervals, resulting in electrophysiological events misaligned with and thus disturbing M-clock function. Elevated sarcoplasmic reticular $[\text{Ca}^{2+}]$ arising from Ca^{2+} or mechanosensitive channel (MSC) activity, or increased RyR2 Ca^{2+} sensitivity, can trigger propagating waves of spontaneous SR Ca^{2+} release thus decoupling M- and C-clock activity. Thus the resulting increased cytosolic $[\text{Ca}^{2+}]$ may transiently increase electrogenic $\text{Na}^+/\text{Ca}^{2+}$ exchange current driving delayed after-depolarizations (DADs) following full AP repolarization¹¹. It may also downregulate longer-term Na^+ channel expression and function compromising conduction. The inward depolarizing nature of $\text{Na}^+/\text{Ca}^{2+}$ exchange also may contribute to SAN automaticity⁸.

Finally, the coloured annotations match the targets identified in Figure 1 to the specific anti-arrhythmic drug classes enumerated by the modernized Oxford scheme⁷. This thus matches therapeutic strategies for anti-arrhythmic treatment to specific components of the model. We thus emerge with a new relatively simple guidance scheme relating arrhythmic mechanisms to treatment strategies. We hope this will facilitate more effective use of what is now available **whilst** encouraging therapeutic advance

References:

1. Kuriachan V, Sumner G, Mitchell L. Sudden cardiac death. *Curr Probl Cardiol* 2017;**40**:133–200.
2. Vaughan Williams E. Classification of antiarrhythmic drugs. In: Sandoe E, Flensted-Jensen E, Olsen K, eds. *Symposium on Cardiac Arrhythmias* Elsinore, Denmark: Astra; 1970.
3. Vaughan Williams E. Classification of antidysrhythmic drugs. *Pharmacol Ther B* 1975;**1**:115–138.
4. Carmeliet E, Vereecke J (Johan). Cardiac cellular electrophysiology. Kluwer Academic Publishers; 2002.
5. Gilmour RF, Zipes DP. Mechanisms of disease: New mechanisms of antiarrhythmic actions. *Nat. Clin. Pract. Cardiovasc. Med.* 2004. p. 37–41.
6. Huang CL-H. Murine models of cardiac arrhythmogenesis. *Physiol Rev* 2017;**97**:283–409.
7. Lei M, Wu L, Terrar DA, Huang CLH. Modernized classification of cardiac antiarrhythmic drugs. *Circulation* 2018;**138**:1879–1896.
8. Lakatta EG, Maltsev VA, Vinogradova TM. A coupled system of intracellular Ca(2+) clocks and surface membrane voltage clocks controls the timekeeping mechanism of the heart's pacemaker. *Circ Res* 2010;**106**:659–673.
9. Antzelevitch C, Burashnikov A. Overview of basic mechanism of cardiac arrhythmia. *Card Electrophysiol Clin* 2011;**3**:23–45.
10. Task force of the working group on arrhythmias The European Society of Cardiology. The Sicilian Gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. *Circulation* 1991;**84**:1831–1851.
11. Bers DM. Calcium cycling and signaling in cardiac myocytes. *Annu Rev Physiol* 2008;**70**:23–49.

Conflicts of interest: none declared.

Acknowledgements: Our work is supported by the Medical Research Council (MR/M001288/1, CLHH, G10002647, G1002082, ML), the Wellcome Trust (105727/Z/14/Z), British Heart Foundation (BHF) (PG/14/79/31102, and PG/15/12/31280 and BHF Centres for Research Excellence (CRE) at Cambridge, CLHH, PG/14/80/31106, PG/16/67/32340, PG/12/21/29473, PG/11/59/29004) and Oxford (ML) and a Chinese Nature Science Foundation Grant (31171085: ML).

Figure legend.

Figure 1: Molecular ion channel and transporter, and signalling components contributing to normal cardiac activity and arrhythmic events and their grouping (AADs 0-VII) into pharmacological targets in the updated Oxford classification scheme⁷. This scheme maps onto a two-clock scheme for normal and abnormal cardiac electrophysiological function. A membrane (M) clock mediates surface electrophysiological changes and conduction of excitation but feeds forwards onto the calcium (C-) clock through producing alterations in cytosolic Ca^{2+} . These trigger cycles of store Ca^{2+} release and re-uptake normally driven by activation and recovery processes in the M-clock. However, the C-clock also feeds back onto the M-clock, altering AP conduction, recovery, and post-recovery stability, besides exerting longer term effects on channel expression. Autonomic sympathetic and parasympathetic control mechanisms act at different control points respectively situated in the C- and M-clocks. cAMP: cyclic 3'5-adenosine monophosphate; Cx: connexin; G_i : inhibitory G protein; G_s : stimulatory G-protein; HCN: hyperpolarisation-activated cyclic nucleotide-gated channel; MSC: mechanically sensitive channel; PKA: protein kinase A; RyR2: cardiac ryanodine receptor, type 2; SERCA: sarcoplasmic reticulum Ca^{2+} -ATPase; PLB: phospholamban; Na^+ , K^+ and Ca^{2+} fluxes through Nav1.4, Kv and Ca1.2 channels also shown.




Figure 1